Great RNS16 Jul 2025 07:08
Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has been awarded a $120,000 G-Rex® grant from ScaleReady, in collaboration with Wilson Wolf Manufacturing and Cell Ready (the "Grant"), to support the optimization and scale-up of the manufacturing process for its lead CAR-T product candidate, HG-CT-1, currently in a Phase I clinical trial for relapsed/refractory acute myeloid leukemia (R/R AML) in adults.
The Grant will enable the Company to further develop a closed-system, G-Rex®-based, manufacturing platform, which is expected to reduce production complexity, streamline regulatory compliance, and significantly lower per-patient manufacturing costs. These advances are critical to the long-term commercial viability of autologous CAR-T therapies such as HG-CT-1.
The Grant also includes Company access to technical consulting in lean bioprocessing, regulatory and CMC strategy, and process engineering, strengthening Hemogenyx's capacity to support future clinical and commercial-scale manufacturing.